Pulse Biosciences (NASDAQ:PLSE) COO Liane Rae Teplitsky Buys 1,024 Shares

Key Points

• Pulse Biosciences COO Liane Rae Teplitsky purchased 1,024 shares at an average price of $48.80, investing nearly $50,000 and increasing her ownership by 49.47% to 3,094 shares. She also made three other purchases totaling roughly $150,000 between August 26 and September 1.
• PLSE shares rose 1.1% to $52.68, near their 52-week high of $54.39. The company recently reported a quarterly loss of $0.36 per share and revenue of $0.43 million, both below analyst expectations.
• Analyst sentiment is mixed but leans positive, with a consensus “Moderate Buy” rating and a $45.25 average price target; institutional investors own approximately 76.95% of the stock.

Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report) COO Liane Rae Teplitsky acquired 1,024 shares of the business's stock in a transaction dated Monday, August 31st. The stock was purchased at an average cost of $48.80 per share, with a total value of $49,971.20. Following the transaction, the chief operating officer owned 3,094 shares of the company's stock, valued at approximately $150,987.20. The trade was a 49.47% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Liane Rae Teplitsky also recently made the following trade(s):

• On Tuesday, September 1st, Liane Rae Teplitsky bought 1,001 shares of Pulse Biosciences stock. The shares were purchased at an average price of $49.95 per share, for a total transaction of $49,999.95.
• On Friday, August 28th, Liane Rae Teplitsky bought 1,034 shares of Pulse Biosciences stock. The stock was purchased at an average cost of $48.35 per share, with a total value of $49,993.90.
• On Wednesday, August 26th, Liane Rae Teplitsky purchased 1,036 shares of Pulse Biosciences stock. The shares were acquired at an average cost of $48.23 per share, for a total transaction of $49,966.28.

Pulse Biosciences Stock Up 1.1%

Shares of PLSE stock traded up $0.59 during mid-day trading on Wednesday, hitting $52.68. 977,767 shares of the company's stock were exchanged, compared to its average volume of 461,050. Pulse Biosciences, Inc has a fifty-two week low of $12.56 and a fifty-two week high of $54.39. The stock has a 50-day simple moving average of $36.93 and a two-hundred day simple moving average of $27.60. The stock has a market cap of $3.65 billion, a price-to-earnings ratio of -44.64 and a beta of 1.63.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.07). Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. The business had revenue of $0.43 million during the quarter, compared to analyst estimates of $0.53 million. As a group, analysts anticipate that Pulse Biosciences, Inc will post -1.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on PLSE. Wall Street Zen upgraded shares of Pulse Biosciences from a "sell" rating to a "hold" rating in a report on Saturday. Oppenheimer reaffirmed an "outperform" rating on shares of Pulse Biosciences in a research report on Tuesday, July 28th. Weiss Ratings restated a "sell (d-)" rating on shares of Pulse Biosciences in a research note on Friday, July 17th. Mizuho set a $45.00 price objective on Pulse Biosciences in a report on Monday, August 10th. Finally, Needham & Company LLC assumed coverage on shares of Pulse Biosciences in a research report on Monday, August 17th. They set a "buy" rating and a $58.00 target price for the company. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $45.25.

Institutional Investors Weigh In On Pulse Biosciences

Hedge funds have recently modified their holdings of the stock. Osterweis Capital Management Inc. purchased a new position in Pulse Biosciences in the 2nd quarter worth approximately $28,000. BNP Paribas Financial Markets boosted its stake in shares of Pulse Biosciences by 63.6% in the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company's stock valued at $26,000 after purchasing an additional 680 shares during the period. Tower Research Capital LLC TRC boosted its stake in shares of Pulse Biosciences by 275.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company's stock valued at $44,000 after purchasing an additional 2,156 shares during the period. Russell Investments Group Ltd. grew its holdings in Pulse Biosciences by 44.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 4,487 shares of the company's stock valued at $79,000 after purchasing an additional 1,372 shares in the last quarter. Finally, Jupiter Topco LLC purchased a new stake in Pulse Biosciences during the 2nd quarter worth $241,000. 76.95% of the stock is currently owned by hedge funds and other institutional investors.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source